UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
 
March 3, 2010
 
NEOPROBE CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
  
0-26520
  
31-1080091
(State or other jurisdiction
  
(Commission
  
(IRS Employer
of incorporation)
 
File Number)
 
Identification No.)

425 Metro Place North, Suite 300, Columbus, Ohio
  
43017
(Address of principal executive offices)
 
(Zip Code)

Registrant's telephone number, including area code
 
(614) 793-7500

 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

Item 2.02.   Results of Operations and Financial Condition.

On March 3, 2010, Neoprobe Corporation (the “Company”) issued a press release regarding its consolidated financial results for the fourth quarter and for the full year ended December 31, 2009.  A copy of the Company’s March 3, 2010, press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 2.02 of this Current Report on Form 8-K, including exhibit 99.1 hereto, shall not be treated as “filed” for purposes of the Securities Exchange Act of 1934, as amended.

Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.

Exhibit
    
Number
  
Exhibit Description
     
99.1
 
Neoprobe Corporation press release dated March 3, 2010, entitled “Neoprobe Announces 2009 Results with Record Medical Device Sales.”

 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Neoprobe Corporation
   
Date: March 3, 2010
By:
/s/ Brent L. Larson
  
   
Brent L. Larson, Vice President, Finance and
Chief Financial Officer

 
3